FindTrial
Sign In

LY3300054

DRUG5 trials

Sponsors

Eli Lilly and Company, Dana-Farber Cancer Institute

Conditions

Breast Cancer (HR+HER2-)CancerCutaneous MelanomaMicrosatellite Instability-High (MSI-H) Solid TumorsNon Small Cell Lung CancerPancreatic CancerRenal Cell CarcinomaSolid Tumor

Phase 1

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
CompletedNCT02791334
Eli Lilly and CompanyBreast Cancer (HR+HER2-), Cutaneous Melanoma, Microsatellite Instability-High (MSI-H) Solid Tumors +2
Start: 2016-06-29End: 2024-06-27Updated: 2024-09-27
A Study of LY3200882 in Participants With Solid Tumors
Active, not recruitingNCT02937272
Eli Lilly and CompanySolid Tumor
Start: 2016-11-21End: 2027-08-01Target: 223Updated: 2026-04-03
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
CompletedNCT03099109
Eli Lilly and CompanySolid Tumor
Start: 2017-04-12End: 2023-08-30Updated: 2023-10-17
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
TerminatedNCT03343613
Eli Lilly and CompanyNon Small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumor +1
Start: 2017-11-17End: 2020-05-04Updated: 2020-06-09
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
CompletedNCT03495323
Dana-Farber Cancer InstituteCancer
Start: 2018-05-16End: 2021-02-01Updated: 2021-04-15

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
2023-01-1219 citations
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
European Journal of Cancer2021-09-2724 citations
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Clinical Cancer Research2021-09-2163 citations
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
2021-03-2024 citations
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Clinical Cancer Research2020-11-2345 citations
Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy
Cancer Research2019-07-018 citations
Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy
Cancer Chemistry2019-07-013 citations
A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
Journal of Clinical Oncology2019-03-1085 citations
Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents
Cancer Research2018-07-012 citations
Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054
Cancer Research2018-07-01
Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model
Cancer Research2017-07-01